AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 17 - (NewsRx.com & NewsRx.net) -- King Pharmaceuticals, Inc. (KG), Bristol, Tennessee, announced that it has obtained an exclusive license from Novavax, Inc. (NOX) to use its proprietary cell line to develop and potentially commercialize recombinant human papillomavirus (HPV) virus-like particle (VLP) vaccines.
Novavax and King are currently working together on manufacturing HPV-16 VLP vaccines being evaluated by the U.S. National Cancer Institute (NCI) in clinical trials. The vaccines are designed to prevent and/or treat HPV-16 infection and associated cervical cancer.
The recombinant HPV-16 VLP vaccines were ...